Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valganciclovir for CMV Prevention in Allogeneic SCT
NCT00330018Phase 3Completed
- Sponsor
- Hadassah Medical Organization
- Start
- Feb 2006
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of valganciclovir in cytomegalovirus infection (CMV), sponsored by Hadassah Medical Organization. Started Feb 2006; status: completed.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00330018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00330018.